Newspaper Advertisement of Financial Results under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
Audited Financial Results
This has reference to our letter dated May 13, 2026, The Board of Directors of the Company at their meeting held on May 29, 2026 have resolved as follows: Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: a) Audited Financial Results (Standalone and Consolidated) of the Company for the fourth quarter and financial year ended March 31, 2026. b) Report of the Auditors on the Audited Financial Results, both for (Standalone and Consolidated) financial statements for the financial year ended March 31, 2026. c) Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Consolidated and Standalone Financial Statements for the Financial Year ended March 31, 2026. The meeting of the Board of Directors of the Company commenced at 11.00 AM and concluded at 11.30 AM. We kindly request you to take the above said on record.
To Consider and approve the Audited Financial Results (Standalone and consolidated) of the Company for the fourth quarter and financial year ended March 31, 2026.
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyTransgene Biotek Ltd 2CIN NO.L85195TG1990PLC011065 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: ANKITA JAIN Designation: COMPLIANCE OFFICER AND COMPANY SECRETARY EmailId: cs@transgenebiotek.com Name of the Chief Financial Officer: PRASAD CHOWDARY Designation: CFO EmailId: accounts@transgenebiotek.com Date: 13/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Non-Applicability of Regulation 32(1) of SEBI.
Compliance - 57 (4)
Non-Applicability of Reg -57 (5) of SEBI LODR Regulations, 2015.
Compliance certificate 7(3)
Compliances Certificate under 74 (5) of SEBI
| Particulars | Dec 2021 | Mar 2022 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 0.00 | 0.09 | 9.99 | 0.05 | 0.05 | 0.05 | 0.06 | 0.08 | 0.05 | 0.05 | 0.05 | 0.05 |
| YOY Revenue Growth % | - | - | - | - | - | -42.12% | -99.41% | 70% | 10% | 7.32% | -6.84% | -28.76% |
| Other Income | 4.38 | 0.08 | 4.38 | 0.04 | 0.05 | 0.65 | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 | 0.15 |
| Total Income | 4.38 | 0.17 | 14.37 | 0.09 | 0.10 | 0.70 | 0.10 | 0.12 | 0.05 | 0.05 | 0.05 | 0.20 |
| Total Expenses + | 268.69 | 2.71 | 28.25 | 0.22 | 0.37 | 0.50 | 0.18 | 0.83 | 0.48 | 0.44 | 0.43 | 0.66 |
| Cost of Materials Consumed | 1.30 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee Benefit Expense | 7.80 | 0.08 | 7.86 | 0.08 | 0.08 | 0.08 | 0.08 | 0.06 | 0.05 | 0.03 | 0.03 | 0.03 |
| Other Expenses | 6.87 | 0.13 | 14.86 | 0.09 | 0.24 | 0.38 | 0.05 | 0.56 | 0.14 | 0.09 | 0.07 | 0.30 |
| Operating Profit | -268.69 | -2.63 | -18.27 | -0.18 | -0.32 | -0.45 | -0.12 | -0.76 | -0.43 | -0.39 | -0.37 | -0.61 |
| OPM % | 0% | -3089.7% | -182.9% | -392% | -718.7% | -919.7% | -200.3% | -989.4% | -876.2% | -735.6% | -685.7% | -1113.6% |
| Profit Before Tax + | -264.31 | -2.55 | -13.88 | -0.13 | -0.27 | 0.20 | -0.07 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 |
| Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tax % | - | - | - | - | - | 0% | - | - | - | - | - | - |
| Profit After Tax | -264.31 | -2.55 | -13.88 | -0.13 | -0.27 | 0.20 | -0.07 | -0.71 | -0.43 | -0.39 | -0.37 | -0.46 |
| EPS (Basic) | -0.35 | -0.34 | -0.02 | 0.00 | 0.04 | 0.03 | -0.01 | -0.09 | -0.06 | -0.05 | -0.05 | -0.06 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2022 |
|---|---|---|---|
| Revenue from Operations | 0.21 | 0.26 | 0.09 |
| YOY Revenue Growth % | -18.99% | 200.73% | - |
| Other Income | 0.15 | 0.78 | 0.21 |
| Total Income | 0.36 | 1.04 | 0.30 |
| Total Expenses + | 2.01 | 1.72 | 10.70 |
| Cost of Materials Consumed | 0.00 | 0.00 | 0.02 |
| Employee Benefit Expense | 0.15 | 0.31 | 0.29 |
| Other Expenses | 0.61 | 1.08 | 0.31 |
| Operating Profit | -1.80 | -1.46 | -10.62 |
| OPM % | -853.6% | -559.8% | -12245.2% |
| Profit Before Exceptional | -1.65 | -0.68 | -10.40 |
| Exceptional Items | 0.00 | 0.00 | 0.00 |
| Profit Before Tax + | -1.65 | -0.68 | -10.40 |
| Tax Expense | 0.00 | 0.00 | 0.00 |
| Tax % | - | - | - |
| Profit After Tax | -1.65 | -0.68 | -10.40 |
| EPS (Basic) | -0.22 | -0.09 | -1.37 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2022 |
|---|---|---|---|
| ASSETS | |||
| Non-Current Assets + | 142.63 | 142.83 | 146.40 |
| Property, Plant & Equipment | 3.09 | 3.29 | 1.85 |
| Capital Work in Progress | 0.00 | 0.00 | 0.00 |
| Non-Current Investments | 0.09 | 0.10 | 0.10 |
| Goodwill | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 4.67 | 4.68 | 9.55 |
| Current Assets + | 1.03 | 1.26 | 0.70 |
| Inventories | 0.03 | 0.03 | 0.09 |
| Trade Receivables | 0.01 | 0.01 | 0.01 |
| Cash and Cash Equivalents | 0.06 | 0.28 | 0.02 |
| Current Investments | 0.00 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | |||
| Total Equity | 8.38 | 10.03 | 17.38 |
| Equity Share Capital | 75.77 | 75.77 | 75.77 |
| Other Equity | -67.39 | -65.74 | -58.39 |
| Non-Current Liabilities | 122.02 | 121.32 | 120.52 |
| Current Liabilities | 13.26 | 12.74 | 9.21 |
| Total Liabilities | 135.28 | 134.06 | 129.72 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2022 |
|---|---|---|---|
| Cash from Operating Activities | -0.01 | 1.20 | 0.09 |
| Cash from Investing Activities | 0.15 | -1.70 | -0.10 |
| Cash from Financing Activities | -0.36 | 0.78 | 0.00 |
| Net Increase/Decrease in Cash | -0.22 | 0.28 | -0.01 |